Email
Password

Forgot Password?


Available June 26, 2015

Course Overview

The NLA's Lipid Academy provides a comprehensive, in-depth indoctrination to lipid science and is open to all health care professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive Lipid Academy course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the Annual Scientific Forum and other advanced lipid training.

This version of the NLA Lipid Academy is offered as a 10-hour online course.

Course Curriculum

  • Lipids, Lipoproteins and Atherosclerosis
  • Landmark Clinical Trials
  • Diagnosis and Clinical Appraisal
  • Pharmacologic Therapies
  • Overview of Clinical Guidelines in Lipid Management
  • Therapeutic Lifestyle Changes

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

Objectives and Accreditation

ACTIVITY DATES

Release Date: June 15, 2015
Expiration Date: June 15, 2018

FEE INFORMATION

This course offered to NLA members at a cost of $550.
All other participants may purchase this course at a cost of $950.

PROGRAM OVERVIEW

The NLA's Lipid Academy Online provides a comprehensive, in-depth indoctrination to lipid science and is open to all health care professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive Lipid Academy course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the Annual Scientific Forum and other advanced lipid training.

ACTIVITY TYPE

Enduring Internet Activity

TARGET AUDIENCE

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

LEARNING OBJECTIVES

At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families.

At the conclusion of this activity, participants should be able to:

  • Describe the functions and sources of cholesterol and triglycerides, including the role of lipoproteins in atherosclerosis
  • Explain the pathogenesis of atherosclerosis
  • Identify the role of inflammation in atherogenesis
  • Discuss clinical trials including their role in lipid and lipoprotein treatment in cardiovascular prevention
  • Review the clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention
  • Apply basic principles of statistics to enhance understanding of clinical trials related to lipid management
  • Compare and contrast the effectiveness of available risk assessment instruments and markers in predicting CV risk in all population groups
  • Identify primary and secondary causes of dyslipidemia
  • Recognize the role of drug therapy in the management of dyslipidemia
  • Review the mechanism of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders
  • Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
  • Describe the appropriate use of lipid-altering drugs in special populations
  • Describe effective diet and lifestyle strategies for long-term obesity and dyslipidemia management
  • Describe the association of specific dietary patterns such as increased sodium and sugar intake, and the increased risk for cardiovascular disease associated morbidity and mortality
  • Compose a clinical care plan for reducing risk of CVD in patients with dyslipidemia
  • Identify the management of dyslipidemia in special populations based on gender, culture, and disease variables
  • Outline current guidelines on the management and treatment of patients with dyslipidemia

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the user's participation, a passing score of 70% on the program post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of the online evaluation available within the paid program. The deadline to claim credit is June 26, 2018.
For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Estimated Time for Completion: 10 hours

COMMERCIAL SUPPORT

There is no commercial support provided for this activity.

CREDIT DESIGNATION

National Lipid Association

CME credit provided by the National Lipid Association


Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Lipid Association designates this Enduring Internet activity for a maximum of 10 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 10 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL0002.

Postgraduate Institute for Medicine

CE credit provided by the Postgraduate Institute for Medicine


Pharmacists
Accreditation Council for Pharmacy EducationPostgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number - 0809-9999-15-230-H01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 10 contact hour(s) (1.000 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
This educational activity for 10 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

For the advanced practice nurse, this activity has 1.5 contact hours of pharmacotherapy content.

FACULTY

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Diplomate, American Board of Clinical Lipidology
Clinical Assistant Professor of Medicine
NYU Medical School
NYU Center for Cardiovascular Disease Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY

Joseph J. Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS
Diplomate, Accreditation Council for Clinical Lipidology
Professor, Clinical Pharmacy and Family Medicine
University of Colorado Denver Anschutz Medical Campus
Aurora, CO

Michael J. Bloch, MD, FACP, FNLA, FASH, FVM
Diplomate, American Board of Clinical Lipidology
Associate Professor, Department of Medicine
University of Nevada School of Medicine
Medical Director, Vascular Care
Renown Institute for Heart and Vascular Health
Renown Regional Medical Center
Reno, NV

Joyce L. Ross, MSN, CRNP, FNLA
Diplomate, Accreditation Council for Clinical Lipidology
Past-President, Preventive Cardiovascular Nurses Association
Consultative Education Specialist, Cardiovascular Risk Intervention
University of Pennsylvania Health System - Retired
Philadelphia, PA


DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through the readerís misunderstanding of content.

PERMISSIONS

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Faculty Financial Disclosures

Speaker
Relationship
Company

Bloch, Michael
Consultant
Aegerion; AstraZeneca; Daiichi- Sankyo; Medtronic; Takeda
Contracted Research
AstraZeneca
Speakers Bureau
AstraZeneca; Bristol-Meyers-Squibb; Daiichi-Sankyo; LipoScience; Pfizer; Takeda

Ross, Joyce
Consultant
Genzyme
Speaker
Abbott Laboratories; Kowa Pharmaceuticals
Speakers Bureau
Amarin; AstraZeneca; Practice Point

Sasseen, Joseph
N/A
Nothing to disclose

Underberg, James
Advisory Board
Aegerion; AstraZeneca; Genzyme; GlaxoSmithKline; Kowa Pharmaceuticals; Merck & Co., Inc.
Consultant
Aegerion; Amarin; Genzyme; Guidepoint Global; LipoScience, Inc.; News Corporation; Novartis; Publicis, Inc.
Contracted Research
Aegerion; Kowa Pharmaceuticals
Speakers Bureau
AstraZeneca; Daiichi Sankyo, Inc.; GlaxoSmithKline; Kowa Pharmaceuticals; LipoScience, Inc.; Merck & Co., Inc.

Planner Financial Disclosures

NLA
N/A
Nothing to Disclose

PIM
N/A
PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

NLA CME Reviewer

Wild, Robert
Consultant
Atherotech, Inc.


Please enter your business email address. We will email you a link that will allow you to select a new password.

Please enter your business email address to start your registration.